Evidence map›Paper›PMID 31654150›Full record

ArticleEuropean journal of clinical pharmacology2020

Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study.

Takaya Uno, Kyoichi Wada, Kouichi Hosomi, Sachi Matsuda, Megumi Morii Ikura, Hiromi Takenaka, Nobue Terakawa, Akira Oita, Satoshi Yokoyama, Atsushi Kawase and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Takaya UnoDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Kyoichi WadaEducation and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, Takatsuki, Japan.
Kouichi HosomiDivision of Clinical Drug Informatics, School of Pharmacy, Kindai University, Higashi-osaka, Japan.
Sachi MatsudaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Megumi Morii IkuraDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Hiromi TakenakaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Nobue TerakawaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Akira OitaDepartment of Pharmacy, National Cerebral and Cardiovascular Center, Suita, Japan.
Satoshi YokoyamaDivision of Clinical Drug Informatics, School of Pharmacy, Kindai University, Higashi-osaka, Japan.
Atsushi KawaseDepartment of Pharmacy, Faculty of Pharmacy, Kindai University, Higashi-osaka, Japan.
Mitsutaka TakadaDivision of Clinical Drug Informatics, School of Pharmacy, Kindai University, Higashi-osaka, Japan. takada@phar.kindai.ac.jp.ORCID http://orcid.org/0000-0003-0834-1005
National Cerebral and Cardiovascular Center · JPKindai University · JPOsaka University of Pharmaceutical Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study investigated the effects of clotrimazole troche on the risk of transplant rejection and the pharmacokinetics of tacrolimus.

methodsThe data mining approach was used to investigate whether the use of clotrimazole increased the risk of transplant rejection in patients receiving tacrolimus therapy. Patient data were acquired from the US Food and Drug Administration's Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the end of 2017. Next, we retrospectively investigated the effect of clotrimazole troche on tacrolimus pharmacokinetics in seven patients who underwent heart transplantation between March and December 2017.

resultsThe FAERS subset data indicated a significant association between transplant rejection and tacrolimus with clotrimazole [reporting odds ratio 1.92, 95% two-sided confidence interval (95% CI) 1.43-2.58, information component 0.81, 95% CI 0.40-1.23]. The pharmacokinetic study demonstrated a significant correlation between trough concentration (C

conclusionImmediate dose adjustments of tacrolimus may be beneficial to avoid transplant rejection when clotrimazole troche is added or discontinued.

Indexed as

AdultAntifungal AgentsBiological AvailabilityClotrimazoleData MiningDrug InteractionsDrug MonitoringFemaleGraft RejectionHeart TransplantationHumansImmunosuppressive AgentsMaleMetabolic Clearance RateMiddle AgedRetrospective StudiesAntifungal AgentsClotrimazoleImmunosuppressive AgentsTacrolimusClotrimazoleDrug interactionHeart transplantationTacrolimusTransplant rejection

Identifiers

PMID31654150
OpenAlexW2982184499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.